<DOC>
	<DOCNO>NCT01243944</DOCNO>
	<brief_summary>This pivotal phase III trial ( CINC424B2301 ) design compare efficacy safety ruxolitinib ( INC424 ) Best Available Therapy ( BAT ) subject polycythemia vera ( PV ) resistant intolerant hydroxyurea ( HU ) .</brief_summary>
	<brief_title>Study Efficacy Safety Polycythemia Vera Subjects Who Are Resistant Intolerant Hydroxyurea : JAK Inhibitor INC424 ( INCB018424 ) Tablets Versus Best Available Care : ( The RESPONSE Trial )</brief_title>
	<detailed_description />
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Subjects diagnose PV least 24 week prior screen accord 2008 World Health Organization criterion Subjects resistant intolerant hydroxyurea Subjects phlebotomy requirement Subjects splenomegaly ( palpable nonpalpable ) spleen volume , measure MRI ( CT applicable subject ) , great equal 450 cubic centimeter Subjects Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Women pregnant nursing Subjects inadequate liver renal function Subjects significant bacterial , fungal , parasitic , viral infection require treatment Subjects active malignancy within past 5 year , exclude specific skin cancer Subjects know active hepatitis HIV positivity Subjects previously receive treatment JAK inhibitor Subjects treat investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>INCB018424</keyword>
</DOC>